

---

Grace Peterson Nursing Research Colloquium

---

## CRNAs and Sugammadex Use: A Qualitative Analysis

Natalia Izquierdo BSN, RN  
*DePaul University*, [nwizquierdo@gmail.com](mailto:nwizquierdo@gmail.com)

Emily Mancewicz BSN, RN  
*DePaul University*, [emilymancewicz@gmail.com](mailto:emilymancewicz@gmail.com)

Follow this and additional works at: <https://via.library.depaul.edu/nursing-colloquium>



Part of the [Anesthesiology Commons](#), [Medical Pharmacology Commons](#), [Nursing Commons](#), and the [Pharmacy Administration, Policy and Regulation Commons](#)

---

Izquierdo, Natalia BSN, RN and Mancewicz, Emily BSN, RN, "CRNAs and Sugammadex Use: A Qualitative Analysis" (2020). *Grace Peterson Nursing Research Colloquium*. 10.  
<https://via.library.depaul.edu/nursing-colloquium/2020/summer/10>

This Event is brought to you for free and open access by the School of Nursing at Via Sapientiae. It has been accepted for inclusion in Grace Peterson Nursing Research Colloquium by an authorized administrator of Via Sapientiae. For more information, please contact [digitalservices@depaul.edu](mailto:digitalservices@depaul.edu).

# CNRAs and Sugammadex Use: A Qualitative Analysis

Natalia Izquierdo BSN, RN & Emily Mancewicz BSN, RN

Faculty Sponsor: Julia Feczko DNP, CRNA

**Background:** The availability of Sugammadex has increased options for Certified Registered Nurse Anesthetists' (CRNAs) and their choice of neuromuscular reversal agents, however administration is impacted by a variety of provider and institutional factors.

**Objectives:** The purpose of this study was to examine and describe the personal and institutional factors impacting the use of Sugammadex in Illinois by CRNAs.

**Method:** A qualitative study design using an open-ended survey yielded 209 responses. The three main themes that emerged were 1) Why CRNAs choose to use or avoid Sugammadex 2) How CRNAs dose Sugammadex and 3) Practice variations existing within the clinical setting.

**Results:** The most commonly reported subthemes included depth of blockade/dosing of paralytic, underlying disease pathology, size of the patient, and cost considerations or availability at their institution.

**Conclusion:** Based upon these main themes and subthemes, it is recommended that institution wide policies be created to reduce variability in provider administration practices if Sugammadex is not widely accepted as standard reversal.

**Keywords:** anesthesia, Sugammadex, neuromuscular blockade reversal, nurse anesthetist

## References:

1. Golembiewski, J. Sugammadex. *J Perianesth Nurs.* 2016; 31(4), 354-357. doi.org/10.1016/j.jopan.2007.09.002
2. Fuchs-Buder T. Less is not always more: sugammadex and the risk of under-dosing. *Eur J Anaesthesiol.* 2010;27(10):849-850. doi:10.1097/eja.0b013e32833dce3a
3. Sugammadex. National Center for Biotechnology Information. PubChem Compound Database. <https://pubchem.ncbi.nlm.nih.gov/compound/Sugammadex#section=Top>. Accessed February 16, 2020.
4. Syed F, Trifa M, Uffman JC, Tumin D, Tobias JD. Monitoring of sugammadex dosing at a large tertiary care pediatric hospital. *Pediatr Qual Saf.* 2018;3(5). doi:10.1097/pq9.000000000000113
5. Herring WJ, Woo T, Assaid CA, et al. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies. *J Clin Anesth.* 2017;41:84-91. doi:10.1016/j.jclinane.2017.06.006.

6. Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. *Br J Anaesth*. 2015;115(5):743-751. doi:10.1093/bja/aev104.
7. Ledowski T, Hillyard S, Kozman A, et al. Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. *Anaesth Intensive Care*. 2012;40(2):340-343. <https://search-ebSCOhost-com.ezproxy.depaul.edu/login.aspx?direct=true&db=ccm&AN=108168684&site=ehost-live&scope=site>. Accessed February 16, 2020.
8. Yang LPH, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. *Drugs*. 2009;69(7):919-942. doi:10.2165/00003495-200969070-00008.
9. Kizilay D, Dal D, Saracoglu KT, Zeynep Eti, Gogus FY, Eti Z. Comparison of neostigmine and sugammadex for hemodynamic parameters in cardiac patients undergoing noncardiac surgery. *Journal of Clinical Anesthesia*. 2016;28:30-35. doi:10.1016/j.jclinane.2015.08.002.

10. Williams R, Bryant H. Sugammadex advice for women of childbearing age. *Anaesthesia*. 2018;73(1):133-134.  
doi:10.1111/anae.14176.
11. Ledowski T, Ong JS, Flett T. Neuromuscular monitoring, muscle relaxant use, and reversal at a tertiary teaching hospital 2.5 years after introduction of sugammadex: changes in opinions and clinical practice. *Anesthesiol Res Pract*. 2015;2015:1-4.  
doi:10.1155/2015/367937
12. Merry AF, Hamblin R. Curtailing the cost of anesthetic drugs: prudent economics or an infringement of clinical autonomy? *Can J Anaesth*. 2015;62(10):1029-1033. doi:10.1007/s12630-015-0443-7
13. Park Y, Raza S, George A, Agrawal R, Ko J. The effect of formulary restrictions on patient and payer outcomes: a systematic literature review. *J Manag Care Spec Pharm*. 2017;23(8):893-901.  
doi:10.18553/jmcp.2017.23.8.893
14. Tabing AK, Ehrenfeld JM, Wanderer JP. Limiting the accessibility of cost-prohibitive drugs reduces overall anesthetic drug costs: a

retrospective before and after analysis. *Can J Anaesth*.

2015;62(10):1045-1054. doi:10.1007/s12630-015-0442-8